Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ALZN

Alzamend Neuro Inc

Feb 11 • 04:00PM ET

1.78

-0.14 -7.29 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN LLY MRK ABBV AZN-D BMY BIIB REGN VRTX GILD

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-5.50	Insider Own	2.53%	Shs Outstand	3.80M	Perf Week	-14.42%
Market Cap	6.77M	Forward P/E	-	EPS next Y	-2.60	Insider Trans	-87.39%	Shs Float	3.71M	Perf Month	-23.61%
Enterprise Value	2.32M	PEG	-	EPS next Q	-0.53	Inst Own	4.66%	Short Float	4.70%	Perf Quarter	-24.58%
Income	-6.47M	P/S	-	EPS this Y	76.38%	Inst Trans	3.20%	Short Ratio	2.15	Perf Half Y	-27.05%
Sales	0.00M	P/B	1.55	EPS next Y	-3.17%	ROA	-116.49%	Short Interest	0.17M	Perf YTD	-2.20%
Book/sh	1.15	P/C	1.52	EPS next 5Y	-	ROE	-144.76%	52W High	10.35 -82.80%	Perf Year	-81.86%
Cash/sh	1.17	P/FCF	-	EPS past 3/5Y	60.75% 30.49%	ROIC	-147.97%	52W Low	1.69 5.33%	Perf 3Y	-99.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.56% 8.01%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	90.82%	Oper. Margin	-	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.58	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.08	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.58	EPS Q/Q	91.47%	SMA20	-16.67%	Beta	-0.24	Target Price	28.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-16.61%	Rel Volume	1.78	Prev Close	1.92
Employees	7	LT Debt/Eq	0.00	Earnings	Dec 31	SMA200	-35.07%	Avg Volume	81.00K	Price	1.78
IPO	Jun 15, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	144,169	Change	-7.29%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy	$8

Jan-26-26 09:40AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-08-26 09:40AM	Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-20-25 07:50AM	EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth? (Zacks) -14.72%
Nov-19-25 08:00AM	Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital (PR Newswire) -5.33%
07:30AM	EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants (Benzinga)
08:00AM	Loading…
Jul-28-25 08:00AM	Alzamend Neuro to Present at the 2025 Military Health System Research Symposium (GlobeNewswire) -6.42%
Jul-23-25 08:00AM	Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs (GlobeNewswire) -5.94%
Jun-16-25 08:00AM	Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule (GlobeNewswire)
May-29-25 08:00AM	Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) +63.86%
May-19-25 08:00AM	Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) +5.88%
May-13-25 08:00AM	Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) -18.83%
07:30AM	EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants (Benzinga)
May-08-25 08:00AM	Alzamend Neuro Announces Reverse Stock Split (GlobeNewswire) -9.40%
May-07-25 08:00AM	Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital (GlobeNewswire) -6.22%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program (Benzinga)
09:55AM	Loading…
Apr-08-25 09:55AM	Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) -5.24%
Mar-28-25 10:42AM	Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey)
Mar-25-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital (GlobeNewswire)
Mar-18-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital (GlobeNewswire) +5.03%
Mar-11-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital (GlobeNewswire)
Mar-04-25 08:10AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital (GlobeNewswire)
Feb-25-25 08:00AM	Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital (GlobeNewswire)
07:30AM	EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 (Benzinga)
Feb-19-25 08:00AM	Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital (Business Wire) -6.48%
07:30AM	EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels (Benzinga)
Jan-23-25 09:40AM	Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-15-25 08:00AM	Alzamend Neuro to Present at the Sequire Investor Summit (Business Wire)
Dec-18-24 08:00AM	Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo (Business Wire)
Dec-13-24 08:15AM	Alzamend Neuro says net cash gained by financing activity $8.3M (TipRanks)
Dec-12-24 08:00AM	Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs (Business Wire)
08:00AM	Loading…
Nov-19-24 08:00AM	Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential (Benzinga)
Oct-16-24 08:00AM	Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's (Benzinga)
Oct-15-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaq Listing Standards (Business Wire)
Oct-10-24 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Groups Virtual Healthcare Conference (Business Wire)
Aug-26-24 08:00AM	Alzamend Neuro Issues Letter to Stockholders (Business Wire) -7.47%
Aug-19-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder (Business Wire) +186.78%
Aug-12-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder (Business Wire)
Aug-06-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder (Business Wire) -9.84%
05:32AM	Alzamend Neuro partners with Mass General for Alzheimers treatment trial (Clinical Trials Arena)
Aug-05-24 09:09AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimers Disease (Business Wire) -22.09%
07:30AM	EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study (Benzinga)
Jul-31-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Jul-12-24 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire)
May-22-24 08:00AM	Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel (Business Wire)
May-14-24 08:00AM	Alzamend Neuro Announces Initial Closing of Private Placement (Business Wire) +18.81%
May-09-24 09:30AM	EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares (Benzinga) +11.74%
08:00AM	Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million (Business Wire)
May-07-24 08:00AM	Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program (Business Wire) -20.02%
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Mar-26-24 05:52AM	ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024 (InvestorPlace)
Dec-18-23 12:03PM	ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024 (InvestorPlace)
12:03PM	ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024 (InvestorPlace)
Dec-11-23 09:30AM	EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year (Benzinga) -6.54%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients (Business Wire)
Nov-20-23 08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients (Business Wire) -17.75%
Nov-16-23 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Nov-13-23 08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire) -6.85%
Oct-30-23 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire) -24.62%
Oct-23-23 09:31AM	EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire)
Oct-02-23 09:30AM	EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder (Benzinga) -8.48%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Sep-22-23 08:00AM	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement (Business Wire)
Aug-30-23 09:30AM	EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Jun-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study (Benzinga)
08:00AM	Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 (Business Wire)
Jun-13-23 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Groups Virtual Healthcare Conference (Business Wire)
May-24-23 08:00AM	3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024 (InvestorPlace) +10.30%
May-11-23 12:38PM	3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year (InvestorPlace)
Apr-04-23 06:30AM	Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Apr-03-23 09:35AM	KILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) +15.29%
09:34AM	EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine (Benzinga)
08:50AM	Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Mar-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial (Benzinga)
08:00AM	Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Mar-17-23 07:09AM	We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully (Simply Wall St.) -12.36%
Mar-16-23 08:00AM	Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update (Business Wire)
Jan-26-23 08:00AM	Alzamend Neuro to Present at Sequire Biotechnology Conference (Business Wire) +9.48%
Jan-04-23 08:00AM	Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial (Business Wire)
Dec-28-22 08:00AM	Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) -11.31%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia (Benzinga)
Dec-13-22 03:52PM	10 Biotech Stocks With The Biggest Upside (Insider Monkey)
Nov-22-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc. (ACCESSWIRE) +10.62%
Nov-15-22 08:00AM	Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline (Business Wire)
Oct-31-22 08:00AM	Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Oct-11-22 10:03AM	Alzamend Neuro, Inc.'s (NASDAQ:ALZN) top owners are individual investors with 46% stake, while 21% is held by private companies (Simply Wall St.) -11.19%
Oct-05-22 12:45PM	Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial (Benzinga) +7.25%
08:00AM	Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimers Subjects (Business Wire)
Sep-29-22 12:29PM	Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Sep-22-22 08:00AM	Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement (Business Wire) -7.63%
Aug-25-22 07:13AM	We Think Alzamend Neuro (NASDAQ:ALZN) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-24-22 08:41AM	6 Penny Stocks With 1,000% Upside Potential (InvestorPlace)
Jul-18-22 10:42AM	Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate (Benzinga)
08:00AM	Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Business Wire)
Jun-20-22 09:22AM	10 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
Jun-03-22 08:00AM	Alzamend Neuro to Present at the 12th Annual LD Micro Invitational (Business Wire)

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AULT MILTON C III	Director	Dec 23 '25	Sale	2.07	1,851	3,825	0	Dec 30 05:54 PM
Horne William B.	Director	Dec 19 '25	Sale	2.12	3,333	7,059	0	Dec 23 04:30 PM
McGrath Lynne Fahey	Director	Oct 23 '25	Sale	2.29	30	69	25	Oct 24 04:30 PM
AULT MILTON C III	Director	Oct 08 '25	Sale	2.44	101,394	247,158	28,657	Oct 10 04:30 PM
AULT MILTON C III	Director	Oct 09 '25	Sale	2.32	20,397	47,390	8,260	Oct 10 04:30 PM
AULT MILTON C III	Director	Oct 06 '25	Sale	2.45	82,033	201,268	26,227	Oct 08 06:50 AM
AULT MILTON C III	Director	Oct 07 '25	Sale	2.49	57,379	142,954	68,848	Oct 08 06:50 AM
AULT MILTON C III	Director	Oct 03 '25	Sale	2.44	65,903	160,889	8,260	Oct 03 09:35 PM
AULT MILTON C III	Director	Oct 01 '25	Sale	2.35	36,777	86,378	94,849	Oct 03 09:35 PM
AULT MILTON C III	Director	Oct 02 '25	Sale	2.39	20,686	49,522	74,163	Oct 03 09:35 PM
AULT MILTON C III	Director	Sep 29 '25	Sale	2.31	38,324	88,490	35,192	Sep 30 07:15 PM
AULT MILTON C III	Director	Sep 26 '25	Sale	2.31	37,738	87,345	73,516	Sep 30 07:15 PM
AULT MILTON C III	Director	Sep 30 '25	Sale	2.33	3,566	8,321	31,626	Sep 30 07:15 PM
AULT MILTON C III	Director	Sep 23 '25	Sale	2.38	43,238	102,721	65,022	Sep 25 08:59 PM
AULT MILTON C III	Director	Sep 24 '25	Sale	2.31	39,140	90,374	25,882	Sep 25 08:59 PM
AULT MILTON C III	Director	Sep 25 '25	Sale	2.31	14,628	33,829	11,254	Sep 25 08:59 PM
AULT MILTON C III	Director	Sep 19 '25	Sale	2.35	77,009	180,856	8,260	Sep 23 04:30 PM
AULT MILTON C III	Director	Sep 18 '25	Sale	2.47	20,870	51,493	85,269	Sep 19 04:50 PM
AULT MILTON C III	Director	Sep 17 '25	Sale	2.45	2,121	5,204	106,139	Sep 19 04:50 PM
AULT MILTON C III	Director	Jul 31 '25	Sale	2.22	100,000	221,550	8,260	Aug 01 04:30 PM
AULT MILTON C III	Director	Jul 30 '25	Sale	2.51	29,449	73,982	108,260	Aug 01 04:30 PM
AULT MILTON C III	Director	Jul 25 '25	Sale	2.90	36,532	105,855	46,020	Jul 29 04:55 PM
AULT MILTON C III	Director	Jul 28 '25	Sale	2.68	8,311	22,314	37,709	Jul 29 04:55 PM
AULT MILTON C III	Director	Jul 23 '25	Sale	2.95	59,516	175,584	92,173	Jul 25 08:00 PM
AULT MILTON C III	Director	Jul 24 '25	Sale	2.93	9,621	28,237	82,552	Jul 25 08:00 PM
AULT MILTON C III	Director	May 12 '25	Sale	5.06	1,213	6,138	8,260	May 14 05:00 PM
AULT MILTON C III	Director	May 12 '25	Sale	5.28	11	58	1,843	May 14 05:00 PM
Hyperscale Data, Inc.	10% Owner	May 12 '25	Proposed Sale	0.54	516,090	278,689		May 09 07:49 PM
Horne William B.	Director	Mar 26 '25	Buy	0.99	3,334	3,285	30,000	Mar 27 07:30 AM
AULT MILTON C III	Director	Mar 21 '25	Buy	1.02	2,905	2,969	85,273	Mar 25 04:30 PM
Katzoff David J	Chief Financial Officer	Mar 21 '25	Buy	1.01	5,000	5,048	5,540	Mar 24 07:30 AM
Horne William B.	Director	Mar 20 '25	Buy	0.98	5,000	4,892	26,666	Mar 20 04:30 PM
Horne William B.	Director	Mar 18 '25	Option Exercise	0.06	10,000	600	16,666	Mar 19 04:30 PM
Horne William B.	Director	Mar 18 '25	Buy	0.97	5,000	4,852	21,666	Mar 19 04:30 PM
AULT MILTON C III	Director	Mar 18 '25	Buy	0.96	5,000	4,810	82,368	Mar 18 07:12 PM
AULT MILTON C III	Director	Mar 12 '25	Buy	0.68	100	68	77,368	Mar 14 05:30 PM

Open in Screener

GPUS

Hyperscale Data Inc

Feb 11 • 04:00PM ET

0.1986

-0.0014 -0.70 %

Industrials • Aerospace & Defense • USA • AMEX

GPUS Hyperscale Data Inc daily Stock Chart

Peers: AMT CCI EQIX DLR SBAC COR IRM GDS BWXT CIA

Index	-	P/E	-	EPS (ttm)	-5.49	Insider Own	0.86%	Shs Outstand	323.39M	Perf Week	-0.70%
Market Cap	69.16M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	320.62M	Perf Month	-40.20%
Enterprise Value	94.29M	PEG	-	EPS next Q	-	Inst Own	8.23%	Short Float	10.09%	Perf Quarter	-43.83%
Income	-44.52M	P/S	0.73	EPS this Y	-	Inst Trans	11.54%	Short Ratio	0.75	Perf Half Y	-71.12%
Sales	94.65M	P/B	0.46	EPS next Y	-	ROA	-15.49%	Short Interest	32.34M	Perf YTD	8.17%
Book/sh	0.43	P/C	0.92	EPS next 5Y	-	ROE	-125.21%	52W High	9.98 -98.01%	Perf Year	-94.51%
Cash/sh	0.22	P/FCF	-	EPS past 3/5Y	91.39% 89.69%	ROIC	-73.29%	52W Low	0.18 10.33%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	26.73% 36.68%	Gross Margin	20.02%	Volatility	8.93% 9.16%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	1.00	EPS Y/Y TTM	99.35%	Oper. Margin	-40.68%	ATR (14)	0.03	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	0.49	Sales Y/Y TTM	-32.83%	Profit Margin	-47.04%	RSI (14)	39.96	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.50	EPS Q/Q	98.53%	SMA20	-14.90%	Beta	2.70	Target Price	-
Payout	-	Debt/Eq	1.76	Sales Q/Q	-21.68%	SMA50	-22.05%	Rel Volume	0.25	Prev Close	0.20
Employees	424	LT Debt/Eq	0.09	Earnings	-	SMA200	-84.71%	Avg Volume	43.07M	Price	0.20
IPO	Dec 17, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	- -8.67%	Trades		Volume	10,664,403	Change	-0.70%

Feb-10-26 06:00AM	Hyperscale Data Bitcoin Treasury at 589.4502 Bitcoin (PR Newswire)
Feb-06-26 06:00AM	Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $0.90 and $0.35, Respectively, as of January 31, 2026 (PR Newswire) +16.42%
Feb-03-26 06:00AM	Hyperscale Data Bitcoin Treasury at 575.5418 Bitcoin; Cash and Bitcoin Holdings at Approximately 142.78% of Market Capitalization (PR Newswire)
Feb-02-26 06:00AM	Hyperscale Data Reaffirms Digital Asset Treasury Policy Amid Bitcoin Volatility; Continues Weekly Dollar-Cost-Averaging Purchases (PR Newswire)
Jan-27-26 06:00AM	Hyperscale Data Bitcoin Treasury at 560.0363 Bitcoin (PR Newswire)
06:00AM	Loading…
Jan-20-26 06:00AM	Hyperscale Data Bitcoin Treasury at 545.4218 Bitcoin (PR Newswire) -8.75%
Jan-16-26 06:00AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire)
Jan-14-26 06:00AM	Hyperscale Data Announces 43 Consecutive Months of Cash Dividend Payments Timely Paid on its Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire)
Jan-13-26 06:00AM	Hyperscale Data Bitcoin Treasury at 539.5929 Bitcoin (PR Newswire)
Jan-07-26 04:38PM	Popular AI stock jumps 30% as Bitcoin treasury exceeds market cap (TheStreet) +40.67%
06:00AM	Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $1.14 and $0.50, Respectively, as of December 31, 2025 (PR Newswire)
Jan-06-26 06:00AM	Hyperscale Data Bitcoin Treasury at 532.6978 Bitcoin and Held Approximately $43.1 Million of Cash as of January 2, 2026 (PR Newswire)
Jan-02-26 06:59PM	AI stock jumps 60% after SEC filing reveals insider buying (TheStreet) +48.69% -10.62%
Dec-30-25 06:00AM	Hyperscale Data Bitcoin Treasury at 519.8687 Bitcoin and Held Approximately $47 Million of Cash as of December 26, 2025 (PR Newswire)
Dec-29-25 06:00AM	Hyperscale Data Establishes 2026 Disclosure Schedule for Bitcoin Treasury, Michigan AI Data Center Progress and Monthly Estimated Asset Updates (PR Newswire) -9.14%
06:00AM	Loading…
Dec-23-25 06:00AM	Hyperscale Data Bitcoin Treasury at 514.9655 Bitcoin and Exceeds 100% of Market Capitalization (PR Newswire)
Dec-19-25 04:30PM	Hyperscale Data Announces "At-the-Market" Offering of Common Stock (PR Newswire) -9.10%
Dec-17-25 06:00AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire)
Dec-16-25 08:42AM	Hyperscale Data and American Bitcoin Expand Corporate Bitcoin Treasuries (Cryptonews)
06:00AM	Hyperscale Data Bitcoin Treasury at 97.5% of Market Capitalization at Approximately $75.5 Million (PR Newswire)
Dec-15-25 06:00AM	Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $1.17 and $0.52, Respectively, as of November 30, 2025 (PR Newswire) -5.20%
Dec-09-25 06:00AM	Hyperscale Data Bitcoin Treasury at Approximately $75 Million (PR Newswire) +7.18%
Dec-02-25 06:00AM	Hyperscale Data Bitcoin Treasury at Approximately $72.25 Million (PR Newswire) +6.45%
Nov-25-25 06:00AM	Hyperscale Data Bitcoin Treasury at Approximately $70.5 Million (PR Newswire)
Nov-24-25 06:00AM	Hyperscale Data Joins the Global Top 100 Public Bitcoin Treasury Companies with Current Holdings of Approximately 382 Bitcoin (PR Newswire) +12.38%
Nov-18-25 04:30PM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire) -6.04%
06:00AM	Hyperscale Data Bitcoin Treasury At Approximately $72.5 Million Representing Approximately 94% of Market Capitalization (PR Newswire)
Nov-17-25 06:00AM	Hyperscale Data Releases Early Bitcoin Update in Light of Market Volatility; the Company Purchased Approximately $6 Million of Bitcoin during November 10-14, 2025 (PR Newswire) -14.84%
Nov-14-25 06:00AM	Hyperscale Data Issues Letter to Stockholders from Executive Chairman (PR Newswire) -7.60%
Nov-12-25 06:00AM	Hyperscale Data Deploying 4,092 New Generation Bitmain Bitcoin Miners, Accelerating Bitcoin Production and Advancing Company Goal of $100 Million Bitcoin Treasury Strategy (PR Newswire)
06:00AM	Loading…
Nov-11-25 06:00AM	Hyperscale Data Bitcoin Treasury Rises to $75.25 Million (PR Newswire)
Nov-06-25 06:00AM	Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $1.02 and $0.47, Respectively, as of October 31, 2025 (PR Newswire)
Nov-05-25 06:00AM	Hyperscale Data Announces Completion of $125 Million At-The-Market Program, Strengthening Its Position as a Bitcoin-Anchored AI Infrastructure Platform Provider (PR Newswire) +11.62%
Nov-04-25 10:11AM	Hyperscale Data Nears $100M Bitcoin Treasury Target With $73.5M in Holdings (CoinGape) -7.03%
06:00AM	Hyperscale Data Bitcoin Treasury Grows to $73.5 Million (PR Newswire)
Oct-29-25 06:30AM	Hyperscale Data Expands Bitcoin Mining Capacity with Order of 2,000 Bitmain S21 Pro Bitcoin Miners (PR Newswire) -18.58%
Oct-28-25 06:30AM	Hyperscale Data Bitcoin Treasury Climbs to $68.8 Million (PR Newswire) +10.16%
Oct-23-25 06:00AM	Hyperscale Data to Launch On-Demand NVIDIA GPU Cloud from Michigan AI Campus (PR Newswire)
Oct-22-25 06:30AM	Hyperscale Data Regains Compliance with NYSE American Continued Listing Standards (PR Newswire)
Oct-21-25 06:00AM	Hyperscale Data Bitcoin Treasury Climbs to $60 Million (PR Newswire) -7.57%
Oct-17-25 06:00AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire) -11.97%
Oct-16-25 06:00AM	Hyperscale Data Takes Delivery of 1,000 Bitmain Antminer S21+ Units and Orders an Additional 1,000 Units (PR Newswire) -5.78%
Oct-14-25 06:00AM	Hyperscale Data Progresses Toward 100% Bitcoin Pairing as Digital Asset Treasury Climbs to $54 Million (PR Newswire) -5.58%
Oct-09-25 06:00AM	Hyperscale Data Reduces Debt by $30 Million, Strengthening Capital Structure to Advance AI and Bitcoin Operations (PR Newswire) -7.02%
Oct-08-25 06:00AM	Hyperscale Data Upgrading 1,000 New Bitmain Antminer S21+Units to Michigan Artificial Intelligence and Bitcoin Campus (PR Newswire) -9.52%
Oct-07-25 06:00AM	Hyperscale Data's Bitcoin Holdings Increase 312% as Company Advances Toward Full Bitcoin Pairing with Market Capitalization as Digital Asset Treasury Allocation Climbs to $41 Million (PR Newswire)
Oct-03-25 06:00AM	Hyperscale Data Announces 39 Consecutive Months of Cash Dividend Payments Timely Paid for Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire) +11.57%
Sep-30-25 06:00AM	Hyperscale Data Continues Toward 100% Bitcoin Pairing as Treasury Allocation Climbs to $24.2 Million (PR Newswire)
Sep-29-25 01:41PM	5 hot crypto stocks to watch today (TheStreet)
06:00AM	Hyperscale Data Upgrading Bitcoin Mining Fleet as Michigan AI Campus Expands (PR Newswire)
Sep-26-25 06:00AM	Hyperscale Data Kicks Off Significant Build-Out at Michigan Campus to Power NVIDIA Blackwell Artificial Intelligence Infrastructure (PR Newswire) +19.56%
Sep-23-25 06:00AM	Hyperscale Data Continues Toward 100% Bitcoin Pairing as Treasury Allocation Climbs to $13.25 Million, Now 39.4% of Market Cap (PR Newswire) -13.69%
Sep-22-25 06:00AM	Hyperscale Data Announces a Special Dividend of Class B Common Stock (PR Newswire) -12.93%
Sep-18-25 06:00AM	Hyperscale Data Marches Toward 100% Bitcoin Pairing as Treasury Climbs to $8 Million, Now 34% of Market Cap (PR Newswire) +30.65%
Sep-17-25 06:00AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire) +6.66%
Sep-16-25 02:10PM	Hyperscale Data Grows Bitcoin Treasury to $7 Million (PR Newswire) -14.73%
06:00AM	Hyperscale Data Reports Bitcoin Treasury Update as of Sunday, September 14; $100 Million Bitcoin Treasury Strategy Underway (PR Newswire)
Sep-15-25 11:35AM	Hyperscale Data Announces $100M Bitcoin Treasury as Company Pivots to AI and Digital Assets (Cryptonews) +22.35%
10:53AM	Hyperscale Data Bets Big on BTC After XRP: Debuts $100M Treasury (Coinspeaker)
06:00AM	Hyperscale Data Launches $100 Million Bitcoin Treasury Strategy as Part of Ongoing Transformation into Pure Play AI and Digital Asset Company (PR Newswire)
Sep-12-25 06:00AM	Hyperscale Data Subsidiary askROI Surpasses One Million App Downloads on Apple App Store and Google Play (PR Newswire)
Sep-11-25 06:00AM	Hyperscale Data Announces Intent to Sell Land Leases and Power Contracts of its Montana Data Properties to Focus on Michigan Flagship Campus (PR Newswire) -8.47%
Sep-10-25 06:30AM	Hyperscale Data's Alliance Cloud Services Expands Collaboration with Silicon Valley Cloud Provider Following First NVIDIA GPU Deployment at Michigan Facility (PR Newswire) +6.83%
Sep-09-25 06:00AM	Hyperscale Data Reports Total Bitcoin Holdings and Total $XRP Purchases (PR Newswire)
Sep-08-25 06:30AM	Hyperscale Data Sees a Potential Increase to Revenue on Growing Momentum in High-Margin Software Platform (PR Newswire) -14.30%
Sep-05-25 06:30AM	Hyperscale Data Reaches 8.1% of Market Capitalization in Bitcoin Holdings Through Mining Operations (PR Newswire)
Sep-04-25 06:30AM	Hyperscale Data Subsidiary Ault Markets Advances Development of StableShare, an Artificial Intelligence Powered Platform for Tokenized Securities (PR Newswire)
Sep-03-25 06:30AM	Hyperscale Data Announces Investments Made by Ault & Company Increased to $55 Million (PR Newswire)
Sep-02-25 08:03AM	Hyperscale Data Unveils Bold Bitcoin Treasury Plan (Benzinga) -22.42%
06:30AM	Hyperscale Data Announces Plan to Add $20 Million in Bitcoin to Its Balance Sheet (PR Newswire)
05:30AM	Hyperscale Data Reports Weekly and Total $XRP Purchases and Total Bitcoin Holdings (PR Newswire)
Aug-29-25 04:22PM	Hyperscale Data Announces "At-the-Market" Offering of Common Stock (PR Newswire)
Aug-25-25 06:30AM	Hyperscale Data Issues Letter to Stockholders (PR Newswire) -7.93%
Aug-22-25 06:30AM	Hyperscale Data Reaffirms Full-Year 2025 Revenue Guidance of $125 Million to $135 Million Following Gresham Worldwide Plan Confirmation (PR Newswire)
Aug-21-25 06:30AM	Hyperscale Data Subsidiary Gresham Worldwide Receives Court Approval of Reorganization Plan; On Track to Emerge from Chapter 11 on October 1, 2025 (PR Newswire)
Aug-19-25 06:30AM	Hyperscale Data Reports Weekly and Total $XRP Purchases (PR Newswire) -7.88%
Aug-15-25 06:30AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire)
Aug-14-25 06:30AM	Hyperscale Data Subsidiary askROI Launches OnlyBulls -- a Mobile-Only Investing App with Your Own AI Market Agent (PR Newswire)
Aug-12-25 06:30AM	Hyperscale Data Reports Weekly and Total $XRP Purchases (PR Newswire)
Aug-08-25 06:30AM	Hyperscale Data Reduces Debt by $25 Million, Strengthening Capital Structure and Bolstering Financial Flexibility Ahead of Michigan AI Data Center Expansion (PR Newswire)
Aug-06-25 06:30AM	Hyperscale Data Reports Approximately $1.8 Million in Bitcoin Mining Revenue for July 2025 (PR Newswire)
Aug-04-25 06:00AM	Hyperscale Data Announces Preliminary Cash and Restricted Cash Position of $27 Million and Total Assets of $214 Million as of June 30, 2025 (PR Newswire) +12.85%
Aug-01-25 06:30AM	Hyperscale Data Enters into an Agreement for a Financing of up to $100 Million (PR Newswire) -8.00%
Jul-31-25 06:00AM	Hyperscale Data Subsidiary askROI Surpasses 700,000 App Downloads on Apple App Store and Google Play (PR Newswire)
Jul-30-25 06:30AM	Hyperscale Data Clarifies $XRP Acquisitions to Remain on Company Balance Sheet (PR Newswire) +5.25%
Jul-29-25 06:45AM	Hyperscale Data Subsidiary Alliance Cloud Services Enters Agreement with Local Utility Provider to Advance Natural Gas Infrastructure for Michigan Data Center (PR Newswire) -8.52%
Jul-28-25 10:53PM	XRP Accumulation Plan Boosts Hyperscale Data Stock by 12% (CoinDesk) +6.84%
06:45AM	Hyperscale Data Announces Weekly Reporting of $XRP Acquisitions Beginning August 12th (PR Newswire)
Jul-25-25 06:45AM	Hyperscale Data Subsidiary AGREE's Minority Holding Fouquet's New York Completes Financing of $145 Million with Goldman Sachs Affiliated Funds (PR Newswire) -16.73%
Jul-23-25 06:45AM	Hyperscale Data Subsidiary BitNile.com Unveils Strategic Vision for $NILE Coin Ecosystem on Solana Blockchain (PR Newswire)
Jul-21-25 06:45AM	Hyperscale Data Targets Full Buildout of 340 MW Michigan AI Data Center Campus in 2029 (PR Newswire) -11.91%
Jul-17-25 06:59AM	Hyperscale Data Announces Preliminary Q2 2025 Revenue of $25.8 Million, Up 45% Year-over-Year (GlobeNewswire)
Jul-16-25 06:59AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (GlobeNewswire)
Jul-15-25 06:59AM	Hyperscale Data Subsidiary askROI Surpasses 590,000 App Downloads on Apple App Store and Google Play (GlobeNewswire) -9.40%
Jul-14-25 06:59AM	Hyperscale Data Reduces Debt by Over $20 Million, Strengthens Balance Sheet Ahead of Planned Michigan AI Data Center Expansion (GlobeNewswire)
Jul-11-25 02:00PM	Hyperscale Data Announces 36 Consecutive Months of Cash Dividend Payments Timely Paid for Series D Cumulative Redeemable Perpetual Preferred Stock (GlobeNewswire) -13.43%
06:59AM	Hyperscale Data Subsidiary Ault Markets Plans to Launch StableShare in Early 2026 - A Platform for Tokenized Securities, Real Assets and Global Markets (GlobeNewswire)
Jul-08-25 06:30AM	Hyperscale Data Reports Approximately $11.2 Million in Bitcoin Mining Revenue Year to Date, Including Approximately $1.5 Million for June 2025 (GlobeNewswire)
Jul-07-25 06:30AM	Hyperscale Data Subsidiary Ault Markets Plans to Launch Solana Validator and Expand Blockchain Infrastructure Capabilities (GlobeNewswire)
Jul-02-25 06:30AM	Hyperscale Data Subsidiary Sentinum is Resuming Bitcoin Mining at Montana Facility (GlobeNewswire)

Hyperscale Data, Inc. owns and manages a data center, and provides mission-critical products for the defense and aerospace, industrial, automotive, telecommunications, medical and biopharma, and textile industries. It operates through the following segments: GWW, TurnOnGreen, Ault Alliance, Crypto-Currency, Real Estate, Ault Disruptive, and Holding Company. The GWW segment offers defense solutions. The TurnOnGreen segment includes commercial electronics solutions. The Ault Alliance segment is involved in commercial lending, activist investing, media, and digital learning. The Crypto-Currency segment includes crypto mining operations. The Real Estate segment consists of hotel operations and other commercial real estate holdings. The Ault Disruptive segment refers to a special purpose acquisition company. The company was founded by Milton C. Ault III in 1969 and is headquartered in Las Vegas, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AULT MILTON C III	Executive Chairman	Dec 31 '25	Buy	0.18	1,000,000	182,900	2,500,005	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 30 '25	Buy	0.19	500,000	94,700	1,500,005	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 30 '25	Buy	0.19	60,000	11,544	220,000	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 31 '25	Buy	0.18	48,800	8,965	268,800	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 29 '25	Buy	22.83	33	753	149	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 29 '25	Buy	0.20	100,000	20,290	1,000,005	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 29 '25	Buy	0.22	59,483	12,804	160,000	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 23 '25	Buy	0.23	10,000	2,250	85,550	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 26 '25	Buy	0.21	10,000	2,140	100,550	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 24 '25	Buy	0.23	5,000	1,128	90,550	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 22 '25	Buy	0.23	200,000	46,640	900,005	Dec 23 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 19 '25	Buy	0.23	100,000	23,290	700,005	Dec 23 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 19 '25	Buy	0.23	15,000	3,393	75,550	Dec 23 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 16 '25	Buy	0.25	5,000	1,267	55,550	Dec 18 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 17 '25	Buy	0.25	5,000	1,246	60,550	Dec 18 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 15 '25	Buy	0.26	125,100	32,426	600,005	Dec 16 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 15 '25	Buy	0.24	12,000	2,918	50,550	Dec 16 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 12 '25	Buy	0.27	3,000	804	38,550	Dec 16 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 10 '25	Buy	0.29	5,000	1,462	30,550	Dec 12 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 11 '25	Buy	0.29	5,000	1,442	35,550	Dec 12 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 03 '25	Buy	0.28	100,000	27,770	474,905	Dec 05 05:00 PM
AULT MILTON C III	Executive Chairman	Dec 01 '25	Buy	0.27	100,000	27,410	374,905	Dec 03 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 02 '25	Buy	0.29	1,000	292	25,550	Dec 03 04:30 PM
AULT MILTON C III	Executive Chairman	Nov 26 '25	Buy	0.29	1,000	294	24,550	Dec 01 04:30 PM
AULT MILTON C III	Executive Chairman	Nov 18 '25	Buy	0.24	205,656	48,782	224,905	Nov 20 05:40 PM
AULT MILTON C III	Executive Chairman	Nov 19 '25	Buy	0.23	50,000	11,450	274,905	Nov 20 05:40 PM
AULT MILTON C III	Executive Chairman	Nov 18 '25	Buy	0.24	3,800	898	23,550	Nov 20 05:40 PM
AULT MILTON C III	Executive Chairman	Sep 11 '25	Buy	0.37	500	185	19,750	Nov 20 05:40 PM
AULT MILTON C III	Executive Chairman	Sep 30 '25	Buy	0.43	2,012	862	19,250	Sep 30 07:15 PM
AULT MILTON C III	Executive Chairman	Sep 26 '25	Buy	0.45	688	307	17,238	Sep 30 07:15 PM
AULT MILTON C III	Executive Chairman	Sep 23 '25	Buy	0.39	1,000	388	16,050	Sep 25 05:00 PM
AULT MILTON C III	Executive Chairman	Sep 24 '25	Buy	0.42	500	209	16,550	Sep 25 05:00 PM
AULT MILTON C III	Executive Chairman	Sep 15 '25	Buy	0.52	6,000	3,099	12,050	Sep 17 08:48 PM
AULT MILTON C III	Executive Chairman	Sep 17 '25	Buy	0.40	3,000	1,211	15,050	Sep 17 08:48 PM
Hyperscale Data, Inc.	10% Owner	Aug 28 '25	Buy	0.01	1,000,000	6,600	13,806,817	Sep 10 07:00 PM
AULT MILTON C III	Executive Chairman	Sep 08 '25	Buy	0.40	2,600	1,050	5,050	Sep 10 07:00 PM
AULT MILTON C III	Executive Chairman	Sep 09 '25	Buy	0.38	1,000	375	6,050	Sep 10 07:00 PM
AULT MILTON C III	Executive Chairman	Aug 22 '25	Buy	0.57	100	57	2,450	Aug 27 04:30 PM
AULT MILTON C III	Executive Chairman	Aug 20 '25	Buy	0.57	10,000	5,724	19,249	Aug 21 05:31 PM
AULT MILTON C III	Executive Chairman	Aug 20 '25	Buy	0.55	1,550	845	2,350	Aug 21 05:31 PM
AULT MILTON C III	Executive Chairman	Aug 19 '25	Buy	0.60	200	120	800	Aug 21 05:31 PM
AULT MILTON C III	Executive Chairman	Jun 17 '25	Buy	1.72	1,000	1,722	9,249	Jun 17 09:42 PM
AULT MILTON C III	Executive Chairman	Jun 17 '25	Buy	2.00	100	200	600	Jun 17 09:42 PM
Hyperscale Data, Inc.	10% Owner	May 12 '25	Proposed Sale	0.54	516,090	278,689		May 09 07:49 PM

ALZN

Alzamend Neuro Inc

GPUS

Hyperscale Data Inc

Upgrade your FINVIZ experience